About Rubra Medicaments
Rubra Medicaments is a publicly listed company based in Mumbai (India) founded in 1995. Pharmaceutical products are supplied to wholesalers, pharmacies, and retail markets. Its Indian entity Centuple Global Limited reported revenue of ₹574 Cr. Rubra Medicaments offers products and services including Consultancy Services. Its focus areas include HealthTech, Pharmacy IT, Supply Chain Management and Procurement. Its competitors include API Holdings and Biddano; 2 of its 2 listed competitors have raised funding.
Company details
Founded in 1995 in Mumbai, India, Rubra Medicaments operates within the pharmaceutical sector. Medical products, devices, and instruments are distributed to wholesalers, pharmacies, and retail channels across domestic markets. Production activities are conducted for outsourcing purposes, supporting various distributors and marketers with essential healthcare supplies. Focus remains on reliable supply chain integration for the industry.
- Headquarters Mumbai, India
- Stage Public
- SectorsHealthcare
- Email••••••••
- Phone•••• ••••
- Website rubramed.com
- Legal Name Checkpoint Trends Limited
- Market Cap₹19.62 Cr
CENTUPLE · BSE
- Share Price₹37.23
+3.82% today
- Revenue₹574 Cr
FY 2025-26 · - YoY
- EBITDA₹2.28 Cr
Margin 0.4%
- Net Profit₹1.50 Cr
FY 2025-26 · +2900.0% YoY
- P/E (TTM)15.5x
P/B 9.3x
- ROE9.4%
ROCE 11.7%
- Debt / Equity0.28
Interest cover 0.0x
Associated legal entities of Rubra Medicaments
Rubra Medicaments is associated with 2 registered companies on The Company Check; the primary company is Centuple Global Limited, a listed company. Each company page carries the filings, financials, charges and directors of that entity.
| Legal entity | Status | Incorporated | Registered in | Revenue (FY 2026) | Employees | Directors | Company page |
|---|---|---|---|---|---|---|---|
| Centuple Global Limited Listed CIN L46307MH1991PLC326598 | Active | 27 Sep 1991 | Nashik, Maharashtra | ₹574 Cr | 7 | View details | |
| Checkpoint Trends Limited CIN L46305MH1991PLC326598 | 27 Sep 1991 | Nashik, Maharashtra, India | View details |
Products & Services of Rubra Medicaments
Rubra Medicaments offers a comprehensive portfolio of products and services, including Consultancy Services.
Offers management and business advisory to support client operations
Board of directors of Centuple Global Limited (Rubra Medicaments)
Centuple Global Limited is the primary company behind Rubra Medicaments. The board of Centuple Global Limited currently have 5 directors; the longest-serving is Shruti Gupta, appointed in 2025. 31 earlier directors have ceased.
| Director | Designation | Appointed | Tenure | Entity |
|---|---|---|---|---|
| Shruti Gupta DIN 10310259 | Director | 04 Apr 2025 | 1 yr 6 mo | Centuple Global Limited |
| Shubham Chaudhary DIN 09298013 | CFO | 17 Sep 2025 | 1 yr 1 mo | Centuple Global Limited |
| Gunjan Gangwal DIN 11413389 | Additional Director | 17 Dec 2025 | 10 mo | Centuple Global Limited |
| Gaurav Kaushik DIN 11613118 | Director | 18 Mar 2026 | 7 mo | Centuple Global Limited |
| Ashish Jain DIN 11613144 | Director | 18 Mar 2026 | 7 mo | Centuple Global Limited |
People of Rubra Medicaments
1 people are tracked at Rubra Medicaments (1 in leadership).
| Name | Role | Group |
|---|---|---|
| Managing Director | Leadership |
Complete people profiles for Rubra Medicaments
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
IPO & Listings of Rubra Medicaments
Rubra Medicaments is a publicly listed company on the BSE with ticker symbol CENTUPLE in India, operating in the Distribution services sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date21 Sep 1995
- Listed onBSE: 531099
- Listed entityCentuple Global Ltd
- Exchange sectorDistribution services
- ISININE396H01019
- Share price₹42.55 (-2.68% on the day) · 2026-05-11
- Volume (last session)8,390
- Analyst consensusNo rating
Financials of Rubra Medicaments
Exchange-reported figures of Centuple Global Limited, the listed company behind Rubra Medicaments (BSE: CENTUPLE).
Financial Highlights
FY 2025-26 · StandaloneRevenue vs Net Profit ₹ Cr
Margin trends
Financial summary ₹ Cr
| Metrics | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Income statement | |||||||
| Revenue | 574 | 0.50 | 1.13 | 1.16 | 2.01 | 0.49 | 0.99 |
| Revenue growth | - | -55.8% | -2.6% | -42.3% | +310.2% | -50.5% | - |
| EBITDA | 2.28 | 0.06 | 0.03 | (0.08) | (0.03) | 0.01 | 0.02 |
| EBITDA margin | +0.4% | +12.0% | +2.7% | -6.9% | -1.5% | +2.0% | +2.0% |
| Profit before tax | 2.28 | 0.05 | 0.02 | (0.08) | (0.03) | 0.01 | 0.05 |
| Net profit | 1.50 | 0.05 | 0.03 | (0.08) | (0.04) | 0.01 | 0.02 |
| Net profit margin | +0.3% | +10.0% | +2.7% | -6.9% | -2.0% | +2.0% | +2.0% |
| EPS (₹) | 2.76 | 0.05 | 0.06 | (0.14) | (0.07) | 0.01 | 0.06 |
| Balance sheet | |||||||
| Total assets | 29.96 | 0.56 | 0.53 | 0.65 | 0.58 | 0.62 | 0.61 |
| Net worth | 23.23 | 0.56 | 0.53 | 0.51 | 0.59 | 0.62 | 0.62 |
| Total debt | 6.74 | 0.00 | 0.00 | 0.15 | 0.00 | 0.00 | 0.00 |
| Cash & bank | 0.09 | 0.03 | 0.01 | 0.03 | 0.02 | 0.52 | 0.00 |
| Net working capital | 29.95 | 0.57 | 0.46 | 0.59 | 0.58 | 0.60 | 0.60 |
| Cash flow | |||||||
| Cash from operations | (28.01) | 0.19 | 0.00 | 0.01 | (0.50) | 0.52 | 0.12 |
| Cash from investing | 0.18 | (0.18) | (0.01) | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash from financing | 27.90 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | (0.26) |
| Particulars | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 279 | 174 | 109 | 11.71 | 0.25 | 0.10 | 0.05 |
| Revenue growth (YoY) | -100.0% | - | - | - | - | - | - | - |
| Other income | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.02 | 0.00 |
| Total expenses | 0.18 | 280 | 173 | 107 | 11.62 | 0.18 | 0.14 | 0.08 |
| EBITDA | (0.18) | (0.38) | 0.77 | 1.79 | 0.09 | 0.07 | (0.04) | (0.03) |
| EBITDA margin | - | -0.1% | +0.4% | +1.6% | +0.8% | +28.0% | -40.0% | -60.0% |
| Depreciation | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Profit before tax | (0.18) | (0.38) | 0.77 | 1.79 | 0.09 | 0.07 | (0.02) | (0.03) |
| Tax | 0.00 | 0.10 | 0.20 | 0.47 | 0.00 | 0.00 | 0.00 | 0.01 |
Financial Statements
| Particulars | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 279 | 174 | 109 | 11.71 | 0.25 | 0.10 | 0.05 |
| Revenue growth (YoY) | -100.0% | - | - | - | - | - | - | - |
| Other income | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.02 | 0.00 |
| Total expenses | 0.18 | 280 | 173 | 107 | 11.62 | 0.18 | 0.14 | 0.08 |
| EBITDA | (0.18) | (0.38) | 0.77 | 1.79 | 0.09 | 0.07 | (0.04) | (0.03) |
| EBITDA margin | - | -0.1% | +0.4% | +1.6% | +0.8% | +28.0% | -40.0% | -60.0% |
| Depreciation | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Profit before tax | (0.18) | (0.38) | 0.77 | 1.79 | 0.09 | 0.07 | (0.02) | (0.03) |
| Tax | 0.00 | 0.10 | 0.20 | 0.47 | 0.00 | 0.00 | 0.00 | 0.01 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Revenue | 574 | 0.50 | 1.13 | 1.16 | 2.01 | 0.49 | 0.99 |
| Revenue growth | - | -55.8% | -2.6% | -42.3% | +310.2% | -50.5% | - |
| Other income | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.03 |
| Total expenses | 572 | 0.44 | 1.10 | 1.24 | 2.04 | 0.48 | 0.97 |
| Employee cost | 0.29 | 0.26 | 0.50 | 0.35 | 0.23 | 0.20 | 0.13 |
| EBITDA | 2.28 | 0.06 | 0.03 | (0.08) | (0.03) | 0.01 | 0.02 |
| EBITDA margin | +0.4% | +12.0% | +2.7% | -6.9% | -1.5% | +2.0% | +2.0% |
| Depreciation | 0.00 | 0.01 | 0.01 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Profit before tax | 2.28 | 0.05 | 0.02 | (0.08) | (0.03) | 0.01 | 0.05 |
| Tax | 0.78 | 0.02 | (0.01) | 0.00 | 0.01 | 0.00 | 0.01 |
| Net profit | 1.50 | 0.05 | 0.03 | (0.08) | (0.04) | 0.01 | 0.02 |
| Net profit margin | +0.3% | +10.0% | +2.7% | -6.9% | -2.0% | +2.0% | +2.0% |
| EPS (₹) | 2.76 | 0.05 | 0.06 | (0.14) | (0.07) | 0.01 | 0.06 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Equity & liabilities | |||||||
| Share capital | 5.47 | 5.47 | 5.47 | 5.47 | 5.47 | 5.47 | 5.47 |
| Reserves & surplus | (3.40) | (4.91) | (4.94) | (5.30) | (5.22) | (5.19) | (5.19) |
| Shareholders' funds (net worth) | 23.23 | 0.56 | 0.53 | 0.51 | 0.59 | 0.62 | 0.62 |
| Secured loans | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Unsecured loans | 6.74 | 0.00 | 0.00 | 0.15 | 0.00 | 0.00 | 0.00 |
| Total debt | 6.74 | 0.00 | 0.00 | 0.15 | 0.00 | 0.00 | 0.00 |
| Total liabilities | 29.96 | 0.56 | 0.53 | 0.65 | 0.58 | 0.62 | 0.61 |
| Assets | |||||||
| Gross block | 0.02 | 0.00 | 0.07 | 0.06 | 0.02 | 0.02 | 0.02 |
| Net block | 0.02 | 0.00 | 0.07 | 0.06 | 0.02 | 0.02 | 0.02 |
| Capital work in progress | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Investments | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Inventories | 1.10 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Sundry debtors | 338 | 0.29 | 0.71 | 0.43 | 0.67 | 0.22 | 0.29 |
| Cash & bank balances | 0.09 | 0.03 | 0.01 | 0.03 | 0.02 | 0.52 | 0.00 |
| Loans & advances | 3.97 | 0.34 | 0.14 | 0.14 | 0.15 | 0.15 | 0.45 |
| Total current assets | 343 | 0.66 | 0.86 | 0.60 | 0.84 | 0.89 | 0.74 |
| Total current liabilities | 313 | 0.09 | 0.40 | 0.01 | 0.26 | 0.29 | 0.14 |
| Net working capital | 29.95 | 0.57 | 0.46 | 0.59 | 0.58 | 0.60 | 0.60 |
| Total assets | 29.96 | 0.56 | 0.53 | 0.65 | 0.58 | 0.62 | 0.61 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Opening cash | 0.03 | 0.01 | 0.03 | 0.02 | 0.52 | 0.00 | 0.14 |
| Net cash from operating activities | (28.01) | 0.19 | 0.00 | 0.01 | (0.50) | 0.52 | 0.12 |
| Net cash from investing activities | 0.18 | (0.18) | (0.01) | 0.00 | 0.00 | 0.00 | 0.00 |
| Net cash from financing activities | 27.90 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | (0.26) |
| Net change in cash | 0.06 | 0.01 | (0.02) | 0.01 | (0.50) | 0.52 | (0.14) |
| Closing cash | 0.09 | 0.03 | 0.01 | 0.03 | 0.02 | 0.52 | 0.00 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Growth | |||||||
| Sales growth | - | -55.8% | -2.6% | -42.3% | +310.2% | -50.5% | - |
| EBITDA growth | +3700.0% | +100.0% | +137.5% | -166.7% | -400.0% | -50.0% | - |
| PBT growth | +4460.0% | +150.0% | +9998.0% | -166.7% | - | -80.0% | +9998.0% |
| Net income growth | +2900.0% | +66.7% | +137.5% | -100.0% | -500.0% | -50.0% | - |
| Revenue CAGR (3Y) | +690.9% | -37.1% | +32.1% | +5.4% | +50.5% | -40.3% | +47.3% |
| EBITDA CAGR (3Y) | - | - | +44.2% | - | -46.0% | - | -20.6% |
| Profitability & leverage | |||||||
| Net income margin | +0.3% | +6.0% | +2.7% | -6.9% | -2.0% | +2.0% | +4.0% |
| Return on capital employed | +11.7% | +1.6% | +0.7% | 0.0% | 0.0% | +0.2% | +0.3% |
| Return on net worth | +9.4% | +0.9% | +1.0% | 0.0% | 0.0% | +0.2% | +0.3% |
| Debt / equity | 0.28 | 0.00 | 0.15 | 0.14 | 0.00 | 0.00 | 0.00 |
| Long-term debt / equity | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest cover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Efficiency & per share | |||||||
| Fixed asset turnover | 57,381.00 | 14.29 | 17.38 | 29.00 | 100.50 | 24.50 | 49.50 |
| Inventory turnover | 1,043.29 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Debtors turnover | 3.40 | 1.00 | 1.98 | 2.11 | 4.52 | 1.92 | 3.41 |
| EPS (₹) | 2.76 | 0.05 | 0.06 | (0.14) | (0.07) | 0.01 | 0.06 |
| Dividend per share (₹) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Book value per share (₹) | 3.78 | 1.02 | 0.97 | 0.30 | 0.45 | 0.51 | 0.50 |
Competitors of Rubra Medicaments
Rubra Medicaments has 2 listed competitors in our database, 2 of them funded. They include API Holdings and Biddano.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| apiholdings.in | 2012 | Mumbai, India | $1.19B | 221 | Digital healthcare tools are offered for pharmacies and clinics management. | |
| biddano.com | 2016 | Pune, India | $6.97M | 19 | Cloud-based supply chain management is provided for pharmacies and hospitals. |
Detailed competitors of Rubra Medicaments
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Rubra Medicaments
The website of Rubra Medicaments (rubramed.com) receives about 1.4K visits a month.
- Monthly visits1.4K
▼ 5.1% vs previous month
Top companies in Pharmacy & Healthcare Retail Systems
2 companies that operate in the same segment as Rubra Medicaments (Pharmacy & Healthcare Retail Systems) in India, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Offers a B2B managed marketplace for pharmacies | 2019 | Bengaluru, Karnataka, India | USD 20.02 M | USD 20.23 M | 218 | |
Digital healthcare tools are offered for pharmacies and clinics management. | 2012 | Mumbai, Maharashtra, India | USD 1.19 B | USD 805.55 M | 215 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Rubra Medicaments
Complete news archive for Rubra Medicaments
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Rubra Medicaments
Rubra Medicaments was founded in 1995.
Rubra Medicaments is headquartered in Mumbai, India. It is registered at Mumbai, Maharashtra, India.
The primary company behind Rubra Medicaments, Centuple Global Limited, reported revenue of ₹574 Cr for FY 2026, up 114662% year on year.
Founded in 1995 in Mumbai, India, Rubra Medicaments operates within the pharmaceutical sector. Medical products, devices, and instruments are distributed to wholesalers, pharmacies, and retail channels across domestic markets. Production activities are conducted for outsourcing purposes, supporting various distributors and marketers with essential healthcare supplies. Focus remains on reliable supply chain integration for the industry.
Rubra Medicaments's top competitors include API Holdings and Biddano.
Rubra Medicaments offers Consultancy Services.
Yes, Rubra Medicaments is publicly traded on BSE under the ticker symbol CENTUPLE.
Rubra Medicaments operates through Centuple Global Limited.
The legal entities of Rubra Medicaments currently have 7 directors, including Shubham Chaudhary, Shruti Gupta, Gunjan Gangwal and others.